The article argues that AI will revolutionize drug discovery long before it can streamline clinical development, creating an abundance of candidate molecules but leaving patient trials as the main constraint. As discovery becomes commoditized and more assets target the same biology, real value will hinge on predictive toxicity, clinical efficacy, and strategic trial design.

• Drug candidate pipelines have doubled in the past decade but novel FDA approvals stayed flat at ~50/year, proving clinical development—not discovery—is the real bottleneck.
• Preclinical assets license for tens of millions, but value jumps to hundreds of millions or low-billions post-Phase 2 proof of concept—a premium set to shrink as AI floods the pipeline with candidates.
• Competition per target is already intense (100+ programs on targets like PD-1/GLP-1) and could double or triple by 2030, making individual molecules less rare and pushing investors to demand better translational data and trial design.
• AI excels at data-rich, fast-feedback problems (virtual screening, protein folding) but struggles with messy, high-variability clinical questions (endpoint selection, immune response prediction, adaptive trials)—so real value will shift to whoever masters those still-slow areas.

The EU's new GMP Annex 22 regulation requires pharmaceutical companies to use fully validated and deterministic AI models in manufacturing. ValidTrace offers a solution by providing pre-validated AI models that meet these compliance standards, ensuring predictable outputs critical for the industry.

• EU's GMP Annex 22 now requires AI used in pharma manufacturing to be fully validated and deterministic, ruling out standard AI's variable outputs for identical inputs.
• ValidTrace sells pre-validated, deterministic AI models plus audit-ready decision logs to turn this compliance burden into a ready-made product.
• Revenue model combines tiered API access, annual model licenses, and enterprise support, with a free "GMP AI Readiness Grader" and open-source library as customer-acquisition hooks.
• Competitive moat is workflow integration/lock-in rather than the models themselves, making switching costly for customers.